These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 15148442)

  • 1. Efficacy of lanreotide 30 mg on prevention of pain relapse after oral refeeding in patients with necrotizing acute pancreatitis. A phase II prospective multicentre study.
    Lévy P; Hastier P; Arotçarena R; Bartolie E; Bougeard-Julien M; Blumberg J; O'Toole D; Ruszniewski P
    Pancreatology; 2004; 4(3-4):229-32. PubMed ID: 15148442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency and risk factors of recurrent pain during refeeding in patients with acute pancreatitis: a multivariate multicentre prospective study of 116 patients.
    Lévy P; Heresbach D; Pariente EA; Boruchowicz A; Delcenserie R; Millat B; Moreau J; Le Bodic L; de Calan L; Barthet M; Sauvanet A; Bernades P
    Gut; 1997 Feb; 40(2):262-6. PubMed ID: 9071942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral refeeding after onset of acute pancreatitis: a review of literature.
    Petrov MS; van Santvoort HC; Besselink MG; Cirkel GA; Brink MA; Gooszen HG
    Am J Gastroenterol; 2007 Sep; 102(9):2079-84; quiz 2085. PubMed ID: 17573797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial of oral refeeding compared with jejunal tube refeeding in acute pancreatitis.
    Pandey SK; Ahuja V; Joshi YK; Sharma MP
    Indian J Gastroenterol; 2004; 23(2):53-5. PubMed ID: 15176536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of somatostatin and its analogues in the treatment of acute pancreatitis: clinical retrospective study].
    Citone G; Perri S; Nardi M; Maira E; Lotti R; Gabbrielli F; Antonellis M; Orsini S
    G Chir; 2001 Apr; 22(4):139-49. PubMed ID: 11370223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral refeeding in patients with mild acute pancreatitis: prevalence and risk factors of relapsing abdominal pain.
    Chebli JM; Gaburri PD; De Souza AF; Junior EV; Gaburri AK; Felga GE; De Paula EA; Forn CG; De Almeida GV; De Castro Nehme F
    J Gastroenterol Hepatol; 2005 Sep; 20(9):1385-9. PubMed ID: 16105125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early and/or immediately full caloric diet versus standard refeeding in mild acute pancreatitis: a randomized open-label trial.
    Lariño-Noia J; Lindkvist B; Iglesias-García J; Seijo-Ríos S; Iglesias-Canle J; Domínguez-Muñoz JE
    Pancreatology; 2014; 14(3):167-73. PubMed ID: 24854611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Digestive refeeding in acute pancreatitis. When and how?].
    Papapietro K; Marin M; Díaz E; Watkins G; Berger Z; Rappoport J
    Rev Med Chil; 2001 Apr; 129(4):391-6. PubMed ID: 11413991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M; Gussoni G; Cuttica CM; Giordano G
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lanreotide autogel is a therapeutic option for patients who develop acute pancreatitis after somatostatin analog treatment.
    Boix E; López P; Pérez-Mateo M; Picó A
    J Endocrinol Invest; 2004 Jun; 27(6):613-4. PubMed ID: 15717663
    [No Abstract]   [Full Text] [Related]  

  • 11. Short- and long-term effect of a long-acting somatostatin analogue, lanreotide (SR-L) on metastatic gastrinoma.
    Gaztambide S; Vazquez JA
    J Endocrinol Invest; 1999 Feb; 22(2):144-6. PubMed ID: 10195383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Use of somatulin in clinical practice].
    Grigor'ev KB; Zuev VK; Bokachev RA
    Klin Med (Mosk); 2004; 82(12):59-61. PubMed ID: 15732723
    [No Abstract]   [Full Text] [Related]  

  • 13. [Application of preparations--analogues of somatostatin in surgical pancreatology].
    Kopchak VM; Kostylev MV; Kopchak KV; Egorova ON; Khomiak IV; Duvalko AV; Romaniv IaV; Pererva LA
    Klin Khir; 2008 Jan; (1):18-21. PubMed ID: 18610850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly.
    Caron P; Beckers A; Cullen DR; Goth MI; Gutt B; Laurberg P; Pico AM; Valimaki M; Zgliczynski W
    J Clin Endocrinol Metab; 2002 Jan; 87(1):99-104. PubMed ID: 11788630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.
    Lucas T; Astorga R;
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):320-6. PubMed ID: 16918950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer.
    Maulard C; Richaud P; Droz JP; Jessueld D; Dufour-Esquerré F; Housset M
    Cancer Chemother Pharmacol; 1995; 36(3):259-62. PubMed ID: 7540120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide.
    Caron P; Morange-Ramos I; Cogne M; Jaquet P
    J Clin Endocrinol Metab; 1997 Jan; 82(1):18-22. PubMed ID: 8989225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of somatostatin and its analogues in pancreatic surgery and pancreatic disorders.
    Friess H; Büchler MW
    Digestion; 1996; 57 Suppl 1():97-102. PubMed ID: 8813484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of oral pancreatic enzyme supplementation on the course and outcome of acute pancreatitis: a randomized, double-blind parallel-group study.
    Kahl S; Schütte K; Glasbrenner B; Mayerle J; Simon P; Henniges F; Sander-Struckmeier S; Lerch MM; Malfertheiner P
    JOP; 2014 Mar; 15(2):165-74. PubMed ID: 24618443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lanreotide Reduces Liver Volume, But Might Not Improve Muscle Wasting or Weight Loss, in Patients With Symptomatic Polycystic Liver Disease.
    Temmerman F; Ho TA; Vanslembrouck R; Coudyzer W; Billen J; Dobbels F; van Pelt J; Bammens B; Pirson Y; Nevens F
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2353-9.e1. PubMed ID: 26073493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.